Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Fluorescent Labeling of Rat-tail Collagen for 3D Fluorescence Imaging.

Bio-protocol

Doyle AD.
PMID: 30112424
Bio Protoc. 2018 Jul 05;8(13). doi: 10.21769/BioProtoc.2919.

Rat tail collagen solutions have been used as polymerizable

Cite
Doyle AD. Fluorescent Labeling of Rat-tail Collagen for 3D Fluorescence Imaging. Bio Protoc. 2018;8(13)doi: 10.21769/BioProtoc.2919.
Doyle, A. D. (2018). Fluorescent Labeling of Rat-tail Collagen for 3D Fluorescence Imaging. Bio-protocol, 8(13), . https://doi.org/10.21769/BioProtoc.2919
Doyle, Andrew D. "Fluorescent Labeling of Rat-tail Collagen for 3D Fluorescence Imaging." Bio-protocol vol. 8,13 (2018). doi: https://doi.org/10.21769/BioProtoc.2919
Doyle AD. Fluorescent Labeling of Rat-tail Collagen for 3D Fluorescence Imaging. Bio Protoc. 2018 Jul 05;8(13). doi: 10.21769/BioProtoc.2919. PMID: 30112424; PMCID: PMC6089535.
Copy Download .nbib Format: NLM
Neurological Complications of Sjögren's Syndrome: Diagnosis and Management.

Current treatment options in rheumatology

McCoy SS, Baer AN.
PMID: 30627507
Curr Treatm Opt Rheumatol. 2017 Dec;3(4):275-288. doi: 10.1007/s40674-017-0076-9. Epub 2017 Oct 24.

PURPOSE OF REVIEW: Neurologic disease is a common extraglandular manifestation of Sjögren's syndrome (SS), the study of which has been hampered both by the lack of uniform definitions for specific neurologic complications and by the imprecision of the tools...

Cite
McCoy SS, Baer AN. Neurological Complications of Sjögren's Syndrome: Diagnosis and Management. Curr Treatm Opt Rheumatol. 2017;3(4):275-288doi: 10.1007/s40674-017-0076-9.
McCoy, S. S., & Baer, A. N. (2017). Neurological Complications of Sjögren's Syndrome: Diagnosis and Management. Current treatment options in rheumatology, 3(4), 275-288. https://doi.org/10.1007/s40674-017-0076-9
McCoy, Sara S, and Baer, Alan N. "Neurological Complications of Sjögren's Syndrome: Diagnosis and Management." Current treatment options in rheumatology vol. 3,4 (2017): 275-288. doi: https://doi.org/10.1007/s40674-017-0076-9
McCoy SS, Baer AN. Neurological Complications of Sjögren's Syndrome: Diagnosis and Management. Curr Treatm Opt Rheumatol. 2017 Dec;3(4):275-288. doi: 10.1007/s40674-017-0076-9. Epub 2017 Oct 24. PMID: 30627507; PMCID: PMC6322693.
Copy Download .nbib Format: NLM
Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents.

Translational cancer research

Tella SH, Kommalapati A, Singhi RK.
PMID: 29863174
Transl Cancer Res. 2018 Feb;7:S81-S84. doi: 10.21037/tcr.2018.01.07.

No abstract available.

Cite
Tella SH, Kommalapati A, Singhi RK. Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents. Transl Cancer Res. 2018;7:S81-S84doi: 10.21037/tcr.2018.01.07.
Tella, S. H., Kommalapati, A., & Singhi, R. K. (2018). Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents. Translational cancer research, 7S81-S84. https://doi.org/10.21037/tcr.2018.01.07
Tella, Sri Harsha, et al. "Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents." Translational cancer research vol. 7 (2018): S81-S84. doi: https://doi.org/10.21037/tcr.2018.01.07
Tella SH, Kommalapati A, Singhi RK. Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents. Transl Cancer Res. 2018 Feb;7:S81-S84. doi: 10.21037/tcr.2018.01.07. PMID: 29863174; PMCID: PMC5983387.
Copy Download .nbib Format: NLM
Need for an Ethical Framework for Testing for Systemic Diseases in Dental Clinics.

Ethics in biology, engineering & medicine

Silveira ML, Chattopadhyay A.
PMID: 24600534
Ethics Biol Eng Med. 2011 Apr 01;2(2):115-136. doi: 10.1615/EthicsBiologyEngMed.2012004545.

Testing for systemic diseases in dental clinics is a potentially attractive avenue for oral health professionals and may be viewed as an opportunity to increase professional reach, expand practice, and improve financial returns. However, several ethical questions arise that...

Cite
Silveira ML, Chattopadhyay A. Need for an Ethical Framework for Testing for Systemic Diseases in Dental Clinics. Ethics Biol Eng Med. 2011;2(2):115-136doi: 10.1615/EthicsBiologyEngMed.2012004545.
Silveira, M. L., & Chattopadhyay, A. (2011). Need for an Ethical Framework for Testing for Systemic Diseases in Dental Clinics. Ethics in biology, engineering & medicine, 2(2), 115-136. https://doi.org/10.1615/EthicsBiologyEngMed.2012004545
Silveira, Marushka Leanne, and Chattopadhyay, Amit. "Need for an Ethical Framework for Testing for Systemic Diseases in Dental Clinics." Ethics in biology, engineering & medicine vol. 2,2 (2011): 115-136. doi: https://doi.org/10.1615/EthicsBiologyEngMed.2012004545
Silveira ML, Chattopadhyay A. Need for an Ethical Framework for Testing for Systemic Diseases in Dental Clinics. Ethics Biol Eng Med. 2011 Apr 01;2(2):115-136. doi: 10.1615/EthicsBiologyEngMed.2012004545. PMID: 24600534; PMCID: PMC3940436.
Copy Download .nbib Format: NLM
Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect.

Research & reviews. Journal of hospital and clinical pharmacy

Kommalapati A, Sikder S, Tella SH.
PMID: 29291253
Res Rev J Hosp Clin Pharm. 2017 Jul;3(2):5-6. Epub 2017 Jun 08.

No abstract available.

Cite
Kommalapati A, Sikder S, Tella SH. Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect. Res Rev J Hosp Clin Pharm. 2017;3(2):5-6
Kommalapati, A., Sikder, S., & Tella, S. H. (2017). Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect. Research & reviews. Journal of hospital and clinical pharmacy, 3(2), 5-6.
Kommalapati, Anuhya, et al. "Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect." Research & reviews. Journal of hospital and clinical pharmacy vol. 3,2 (2017): 5-6.
Kommalapati A, Sikder S, Tella SH. Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect. Res Rev J Hosp Clin Pharm. 2017 Jul;3(2):5-6. Epub 2017 Jun 08. PMID: 29291253; PMCID: PMC5744671.
Copy Download .nbib Format: NLM
International Classification of Diseases Codes and their Use in Dentistry.

Journal of dental, oral and craniofacial epidemiology

Weatherspoon D, Chattopadhyay A.
PMID: 25879045
J Dent Oral Craniofac Epidemiol. 2013 Oct;1(4):20-26.

The deadline for replacing International Classification of Diseases, 9th edition (ICD-9) code sets with the newer ICD-10 code sets, used for the reporting of medical diagnoses and inpatient hospital procedures, was recently updated to occur at a date no...

Cite
Weatherspoon D, Chattopadhyay A. International Classification of Diseases Codes and their Use in Dentistry. J Dent Oral Craniofac Epidemiol. 2013;1(4):20-26
Weatherspoon, D., & Chattopadhyay, A. (2013). International Classification of Diseases Codes and their Use in Dentistry. Journal of dental, oral and craniofacial epidemiology, 1(4), 20-26.
Weatherspoon, Darien, and Chattopadhyay, Amit. "International Classification of Diseases Codes and their Use in Dentistry." Journal of dental, oral and craniofacial epidemiology vol. 1,4 (2013): 20-26.
Weatherspoon D, Chattopadhyay A. International Classification of Diseases Codes and their Use in Dentistry. J Dent Oral Craniofac Epidemiol. 2013 Oct;1(4):20-26. PMID: 25879045; PMCID: PMC4394630.
Copy Download .nbib Format: NLM
Sex and race or ethnicity disparities in opioid prescriptions for dental diagnoses among patients receiving Medicaid.

Journal of the American Dental Association (1939)

Janakiram C, Chalmers NI, Fontelo P, Huser V, Mitnik GL, Iafolla TJ, Brow AR, Dye BA.
PMID: 31561765
J Am Dent Assoc. 2019 Oct;150(10):e135-e144. doi: 10.1016/j.adaj.2019.06.016.

BACKGROUND: The objective of this study was to identify specific factors (sex, race or ethnicity, and health care provider type) associated with patient receipt of an opioid prescription after a dental diagnosis.METHODS: The authors used Medicaid claims dated from...

Cite
Janakiram C, Chalmers NI, Fontelo P, et al. Sex and race or ethnicity disparities in opioid prescriptions for dental diagnoses among patients receiving Medicaid. J Am Dent Assoc. 2019;150(10):e135-e144doi: 10.1016/j.adaj.2019.06.016.
Janakiram, C., Chalmers, N. I., Fontelo, P., Huser, V., Mitnik, G. L., Iafolla, T. J., Brow, A. R., & Dye, B. A. (2019). Sex and race or ethnicity disparities in opioid prescriptions for dental diagnoses among patients receiving Medicaid. Journal of the American Dental Association (1939), 150(10), e135-e144. https://doi.org/10.1016/j.adaj.2019.06.016
Janakiram, Chandrashekar, et al. "Sex and race or ethnicity disparities in opioid prescriptions for dental diagnoses among patients receiving Medicaid." Journal of the American Dental Association (1939) vol. 150,10 (2019): e135-e144. doi: https://doi.org/10.1016/j.adaj.2019.06.016
Janakiram C, Chalmers NI, Fontelo P, Huser V, Mitnik GL, Iafolla TJ, Brow AR, Dye BA. Sex and race or ethnicity disparities in opioid prescriptions for dental diagnoses among patients receiving Medicaid. J Am Dent Assoc. 2019 Oct;150(10):e135-e144. doi: 10.1016/j.adaj.2019.06.016. PMID: 31561765; PMCID: PMC6768087.
Copy Download .nbib Format: NLM
A patient with MEN1 typical features and MEN2-like features.

International journal of endocrine oncology

El-Maouche D, Welch J, Agarwal SK, Weinstein LS, Simonds WF, Marx SJ.
PMID: 27594983
Int J Endocr Oncol. 2016 May;3(2):89-95. doi: 10.2217/ije-2015-0008. Epub 2016 Apr 08.

Multiple endocrine neoplasia (MEN) type 1 (MEN1) and 2 (MEN2) rarely co-exist in one case. Here we report a patient with features of both syndromes. The patient presented with typical MEN1 features plus pheochromocytoma and thickened corneal nerves. She...

Cite
El-Maouche D, Welch J, Agarwal SK, et al. A patient with MEN1 typical features and MEN2-like features. Int J Endocr Oncol. 2016;3(2):89-95doi: 10.2217/ije-2015-0008.
El-Maouche, D., Welch, J., Agarwal, S. K., Weinstein, L. S., Simonds, W. F., & Marx, S. J. (2016). A patient with MEN1 typical features and MEN2-like features. International journal of endocrine oncology, 3(2), 89-95. https://doi.org/10.2217/ije-2015-0008
El-Maouche, Diala, et al. "A patient with MEN1 typical features and MEN2-like features." International journal of endocrine oncology vol. 3,2 (2016): 89-95. doi: https://doi.org/10.2217/ije-2015-0008
El-Maouche D, Welch J, Agarwal SK, Weinstein LS, Simonds WF, Marx SJ. A patient with MEN1 typical features and MEN2-like features. Int J Endocr Oncol. 2016 May;3(2):89-95. doi: 10.2217/ije-2015-0008. Epub 2016 Apr 08. PMID: 27594983; PMCID: PMC5008851.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries